Danaher (NYSE:DHR – Get Free Report) issued its quarterly earnings data on Tuesday. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17, Zacks reports. The business had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.93%. The business’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.71 EPS. Danaher updated its FY 2025 guidance to 7.700-7.800 EPS.
Danaher Trading Down 1.2%
DHR opened at $218.06 on Thursday. The company’s 50 day moving average is $202.24 and its 200-day moving average is $197.73. Danaher has a 1-year low of $171.00 and a 1-year high of $260.88. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The company has a market cap of $156.14 billion, a P/E ratio of 44.96, a PEG ratio of 3.20 and a beta of 0.77.
Danaher Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 27.23%.
Analyst Ratings Changes
View Our Latest Stock Analysis on DHR
Insider Transactions at Danaher
In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Danaher
A number of institutional investors have recently added to or reduced their stakes in the business. Evergreen Capital Management LLC grew its holdings in Danaher by 12.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 3,920 shares of the conglomerate’s stock worth $776,000 after acquiring an additional 445 shares during the last quarter. 44 Wealth Management LLC grew its holdings in Danaher by 7.8% during the 2nd quarter. 44 Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock worth $250,000 after acquiring an additional 92 shares during the last quarter. Duquesne Family Office LLC bought a new stake in Danaher during the 2nd quarter worth approximately $4,879,000. MUFG Securities EMEA plc grew its holdings in Danaher by 4.4% during the 2nd quarter. MUFG Securities EMEA plc now owns 44,884 shares of the conglomerate’s stock worth $8,867,000 after acquiring an additional 1,885 shares during the last quarter. Finally, SkyView Investment Advisors LLC grew its holdings in Danaher by 1.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 5,174 shares of the conglomerate’s stock worth $1,029,000 after acquiring an additional 83 shares during the last quarter. 79.05% of the stock is owned by institutional investors.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- How to Use the MarketBeat Stock Screener
- Breakout Momentum Plays You Need to Know About
- Investing in Construction Stocks
- Quanta Services: The Backbone of the AI Data Center Push
- Canadian Penny Stocks: Can They Make You Rich?
- Archer’s Recent String of Victories Signals a New Phase of Growth
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.